InsidersTradesSigma
Track the 올릭스 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are listed on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 올릭스 has recorded 3 insider filings. Market capitalisation: €2,746.7bn. The latest transaction was disclosed on 7 July 2026 (Other). Among the most active insiders: 미래에셋자산운용. Every trade is free.
Analysts rate 올릭스 Strong Buy (bullish), based on 1 analysts. Average price target: ₩160,000.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
올릭스 is a biotechnology company focused on developing RNA-based therapies. It is listed on the XKRX market.